LBA33 Maintenance olaparib rechallenge in patients (pts) with ovarian carcinoma (OC) previously treated with a PARP inhibitor (PARPi): Phase IIIb OReO/ENGOT Ov-38 trial

Éric Pujade-Lauraine ,Frédèric Selle ,Claudio Zamagni ,Florian Heitz ,Isabelle Ray‐Coquard ,Bernard Asselain ,Laurence Gladieff ,Nicoletta Colombo ,Coraline Dubot ,Christopher Blakeley ,Radosław Mądry ,María Jesús Rubio-Pérez ,Brian Shaw ,Kristina Lindemann ,Frederik Marmé ,Ros Glasspool ,Giovanni Scambia ,Ana Oaknin ,Paolo Scollo ,Andrés Redondo

doi:10.1016/j.annonc.2021.08.2110

LBA33 Maintenance olaparib rechallenge in patients (pts) with ovarian carcinoma (OC) previously treated with a PARP inhibitor (PARPi): Phase IIIb OReO/ENGOT Ov-38 trial

Éric Pujade-Lauraine , Frédèric Selle + Show 18 more

Open Access

https://doi.org/10.1016/j.annonc.2021.08.2110

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2021
Citations: 46	License type: publisher-specific-oa

#Rechallenge In Patients #Phase IIIb + Show 3 more

Abstract
Full-Text PDF
Similar Papers

Abstract

LBA33 Maintenance olaparib rechallenge in patients (pts) with ovarian carcinoma (OC) previously treated with a PARP inhibitor (PARPi): Phase IIIb OReO/ENGOT Ov-38 trial

Full Text